Fluticasone Propionate And Salmeterol Powder
Product Images NDC 0093-7516

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 0093-7516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure diagram of the active ingredient fluticasone propionate, one of the components in the combination drug fluticasone propionate and salmeterol for respiratory inhalation, as labeled by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

2 (Image 10)

An instructional illustration showing a pair of hands holding a respiratory inhaler device with a thumb pressing down on the mouthpiece while an arrow points to the right, indicating the direction of inhaler actuation or sliding.*

FDA Label Image

Figure D (Image 11)

Illustration showing a woman holding a respiratory inhalation device near her mouth, demonstrating how to use the device. The image is related to the administration of inhaled powder medication.*

FDA Label Image

Figure E (Image 12)

An instructional illustration depicting a person using a respiratory inhaler device by placing it in their mouth for inhalation. The image demonstrates the proper use of an inhalation powder inhaler, relevant for drugs like fluticasone propionate and salmeterol powder for respiratory administration.*

FDA Label Image

1 (Image 13)

An instructional illustration showing hands holding a respiratory inhalation device labeled with fluticasone propionate and salmeterol. The image includes an arrow indicating a sliding or pulling motion with the thumb, demonstrating how to operate or prepare the inhaler for use.*

FDA Label Image

Figure G (Image 14)

An instructional illustration showing a woman rinsing her mouth over a sink with water from a faucet, intended to demonstrate proper oral hygiene after using a respiratory inhaler powder medication.*

FDA Label Image

1 (Image 15)

An illustration of a respiratory inhalation device labeled for fluticasone propionate and salmeterol with detailed view highlighting a dose counter reading '5'. The device includes a label showing product information, including active ingredients and strength of 500 mcg and 50 mcg respectively.*

FDA Label Image

1 (Image 16)

Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, USP 100 mcg/50 mcg by Teva Pharmaceuticals USA, Inc. The label includes product strength, dosage form as powder for oral inhalation, and a depiction of the inhaler device containing 60 blisters. Important usage and storage instructions, as well as manufacturing details, are also presented on the label.*

FDA Label Image

1 (Image 17)

Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, USP 250 mcg/50 mcg by Teva Pharmaceuticals USA, Inc. The label shows a foil strip of 60 blisters in an inhalation device. It includes dosage information, usage instructions, storage guidelines, and manufacturer details. The label emphasizes use for oral inhalation only and contains directions for proper inhaler use.*

FDA Label Image

1 (Image 18)

Fluticasone Propionate and Salmeterol Inhalation Powder, USP 500 mcg/50 mcg for oral inhalation only, presented in a carton containing 1 inhalation device with 1 foil strip of 60 blisters. The label shows dosing strength, administration route, manufacturer information (Teva Pharmaceuticals USA, Inc.), handling instructions, and storage guidelines. Includes an image of the green inhaler device on the front panel.*

FDA Label Image

1 (Image 2)

Chemical structure diagram showing the molecular formulas for fluticasone propionate and salmeterol, the active ingredients of the inhalation powder product by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

1 (Image 3)

Line graph depicting percent change in FEV1 over 12 weeks and at endpoint for fluticasone propionate and salmeterol inhalation powder 100mcg/50mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph includes sample sizes and distinct markers for each treatment group.*

FDA Label Image

1 (Image 4)

A line graph depicting the percent change in FEV1 (forced expiratory volume in one second) over a 12-hour period following administration of different treatments: fluticasone propionate and salmeterol inhalation powder (100 mcg/50 mcg twice daily), salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The y-axis represents percent change in FEV1, and the x-axis represents time in hours after baseline at Day 1.*

FDA Label Image

1 (Image 5)

This is a line graph showing the percent change in FEV1 relative to Day 1 baseline over a 12-hour period at Week 12. The graph compares four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The y-axis shows percentage change in FEV1, and the x-axis shows time in hours from baseline.*

FDA Label Image

1 (Image 6)

A line graph showing percentage change in FEV1 over a 24-week period comparing three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The fluticasone propionate and salmeterol group shows the highest sustained improvement. Sample sizes are provided at multiple time points for each group.*

FDA Label Image

1 (Image 7)

A line graph depicting the percent change in FEV1 from baseline over 24 weeks for fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, fluticasone propionate 250 mcg alone, and placebo. The graph shows higher improvement with the combination inhalation powder compared to the others. Sample sizes vary at different time points throughout the study.*

FDA Label Image

1 (Image 8)

Illustration of a respiratory powder inhaler device for fluticasone propionate and salmeterol. Labeled parts include the outer case, mouthpiece, lever, thumb grip, and counter. The diagram highlights components used for inhalation administration of the medication.*

FDA Label Image

1 (Image 9)

An instructional diagram showing a hand holding a powder inhaler device for respiratory administration. The illustration demonstrates how to operate the inhaler by pressing or sliding a component, indicated by a directional arrow.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.